Genfit SA (GNFT.PA) (EPA:GNFT)’s share price dropped 0.7% during trading on Wednesday . The company traded as low as €4.58 ($5.39) and last traded at €4.62 ($5.43). Approximately 458,648 shares changed hands during mid-day trading, The stock had previously closed at €4.65 ($5.47).
The firm has a 50 day moving average price of €4.37 and a two-hundred day moving average price of €4.11.
Genfit SA (GNFT.PA) Company Profile (EPA:GNFT)
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Further Reading: Overbought
Receive News & Ratings for Genfit SA (GNFT.PA) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit SA (GNFT.PA) and related companies with MarketBeat.com's FREE daily email newsletter.